학술논문
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program
Document Type
Article
Author
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 10 January 2023, 41(2):154-162)
Subject
Language
English
ISSN
15277755
0732183X
0732183X